|September 3, 2013|
|05:58 EDT||CYTK, AMGN||Amgen, Cytokinetics announce presentation of Phase 2 data of Omecamtiv Mecarbil|
Amgen (AMGN) and Cytokinetics (CYTK) announced the first presentation of data from the ATOMIC-AHF, or Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure, study at the ESC Congress, organized by the European Society of Cardiology, in Amsterdam. ATOMIC-AHF was a randomized, double-blind, placebo-controlled Phase 2 study that enrolled 613 patients hospitalized with acute heart failure, or AHF, treated for 48 hours with omecamtiv mecarbil or placebo and designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and potential efficacy of an intravenous formulation of omecamtiv mecarbil in patients with AHF. The study did not meet its primary endpoint of dyspnea response as measured by the 7-point Likert scale through 48 hours but showed favorable dose and concentration-related trends on dyspnea response.
News For AMGN;CYTK From The Last 14 Days
Check below for free stories on AMGN;CYTK the last two weeks.
|December 6, 2013|
|08:31 EDT||AMGN||Amgen unit, International Myeloma Foundation announce partnership|
The International Myeloma Foundation and Onyx Pharmaceuticals, an Amgen subsidiary, announced the start of a multi-year collaboration in support of the IMF's Black Swan Research Initiative. The BSRI is led by a multinational consortium of leading myeloma experts who are studying and harnessing new technologies and treatments with the goal of developing a cure for myeloma.
|06:19 EDT||AMGN||Amgen price target lowered to $131 from $139 at Citigroup|
Citigroup lowered its price target for Amgen shares to $131 after dropping its estimates for the company's myeloma drug Kyprolis to below consensus. Citi believes the drug's inconvenience and cardiac toxicities are limiting its uptake and while drugs in late stage development offer far more appealing profiles. Citi, however, keeps a Buy rating on Amgen.
|December 3, 2013|
|09:37 EDT||AMGN||Active equity options trading on open|
Active equity options trading on open according to Track Data: CELG YHOO BX ARIA GS NXPI DG AMGN SLW MRK
|07:42 EDT||CYTK||Cytokinetics announces closing of enrollment into Phase IIb trial of Tirasemtiv |
Subscribe for More Information
|December 2, 2013|
|14:03 EDT||AMGN||Amgen pegfilgrastim granted orphan status for treatment of myelosuppression|
|November 27, 2013|
|13:05 EDT||AMGN||Amgen Neupogen granted orphan designation by FDA|
The drug received orphan designation for treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident. Reference Link
|November 26, 2013|
|16:14 EDT||AMGN||Amgen coverage resumed with an Overweight at Piper Jaffray|